These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
252 related items for PubMed ID: 34326129
1. An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients. Dietlein F, Kobe C, Vázquez SM, Fischer T, Endepols H, Hohberg M, Reifegerst M, Neumaier B, Schomäcker K, Drzezga AE, Dietlein M. J Nucl Med; 2022 Apr; 63(4):573-583. PubMed ID: 34326129 [Abstract] [Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Apr; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
3. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer. Vázquez SM, Endepols H, Fischer T, Tawadros SG, Hohberg M, Zimmermanns B, Dietlein F, Neumaier B, Drzezga A, Dietlein M, Schomäcker K. Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181 [Abstract] [Full Text] [Related]
4. Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer. Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S, Petto S, Bartholomä M, Ezziddin S. Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2899-2909. PubMed ID: 37148297 [Abstract] [Full Text] [Related]
15. Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F. Theranostics; 2017 Jul; 7(18):4359-4369. PubMed ID: 29158832 [Abstract] [Full Text] [Related]
16. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L. J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024 [Abstract] [Full Text] [Related]
18. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U. Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344 [Abstract] [Full Text] [Related]
19. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):678-688. PubMed ID: 27889802 [Abstract] [Full Text] [Related]